Kayentis and RWS have formalised a partnership aimed at reducing inconsistency in clinician-reported outcome assessments in complex clinical studies, with an initial focus on Central Nervous System trials. The agreement combines Kayentis’ eCOA platform with RWS’s rater training, qualification, certification, and monitoring services.
CNS studies are especially exposed to variability. Long study durations, difficult assessment scales, and vulnerable patient populations can all affect how consistently clinicians score and administer endpoints. Small differences across sites or over time can weaken endpoint reliability and complicate the interpretation of trial results.
The combined offer is designed to address that problem from both sides. Kayentis provides the electronic Clinical Outcome Assessment platform, while RWS supplies indication-specific rater training and certification. The partnership also links platform permissions to certification status, allowing only appropriately qualified clinicians to complete certain assessments. That creates a tighter operational link between who is trained, who is authorised, and how the data is captured.
For sponsors and CROs, the appeal is partly technical and partly operational. Better control over access, assessment consistency, and monitoring can improve the quality of clinician-reported outcome data, while a more integrated workflow can reduce friction across vendors in global studies. The arrangement is also intended to strengthen inspection readiness by improving traceability around both training and data capture.
RWS has recently expanded its CNS rater training services, while Kayentis has continued to develop its Clin’form platform and build out neuroscience expertise around it. The new partnership brings those strands together in a more formal structure aimed at sponsors running studies where endpoint quality depends on consistent assessment across multiple sites over long periods.
The joint solution is available immediately for CNS and other complex trials. As digital systems become standard across clinical operations, competition between providers is shifting towards how well they control variability, access, and data integrity across the full trial process.
